Pillars of growth
Heavy bet for R&D
as a future
growth engine
Heavy bet on R&D
as a future
growth engine
Biosimilars
A great growth opportunity for ROVI in a market that totals more than 1,000 million euros in Europe.
Pharmaceutical products
Diversified portfolio of innovative own and licensed products protected by patents.
Low Molecular Weight Heparin
ROVI's principal product, a low-molecular-weight heparin developed in-house.
Contract manufacturing
High production capacity with four manufacturing plants for prefilled syringes and oral solid forms.
Rovi in figures
+119%
Net profit of the businessin 2019
+46%
2019 LMWHglobal sales
65 countries
LMWH presence through strategic alliances with international partners
6 plants
for manufacturing own and third-party products in Spain
€29,3 Mn
of investment in R&D in 2019 Commitment to innovation
7 countries
Direct presence through subsidiaries to market Enoxaparin
Information for investors
Detailed information for investors and shareholders. All of ROVI’s information, results and figures presented clearly and transparently.
Last news on Rovi
28/07/2021
First half 2021 results presentation
Operating income, growth figures, profitability and how our products have behaved.
28/07/2021
First Half 2021 Results Press Release
Download our press release published on 28 July to find out the financial results for the first half of 2021.
Last annual report
Annual Report 2020
Last regular
public information